Protagonist

Alucio™ Unveils New Meeting Features in Beacon to Elevate HCP Engagement

Retrieved on: 
Wednesday, February 28, 2024

SAN FRANCISCO, Feb. 28, 2024 /PRNewswire-PRWeb/ -- Alucio™, a fast-growing provider of cloud-based software for the life sciences industry, today announced important enhancements to the presentation mode within Beacon. Beacon is a modern content activation and Healthcare Professional (HCP) engagement platform built specifically for Medical Science Liaisons (MSLs), Medical Affairs professionals, and Market Access teams.

Key Points: 
  • Beacon is a modern content activation and Healthcare Professional (HCP) engagement platform built specifically for Medical Science Liaisons (MSLs), Medical Affairs professionals, and Market Access teams.
  • Users are reacting very positively to these enhancements and the other engagement features in Beacon.
  • "We are very excited to release these new features to further enhance the effectiveness of meetings conducted from Beacon," says Lauren Keyes, Alucio Director of Product Management.
  • "We continue to focus on making the meeting experience on Beacon as easy and impactful as possible."

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

Retrieved on: 
Friday, September 22, 2023

VANCOUVER, British Columbia, Sept. 22, 2023 /PRNewswire/ -- USA News Group - Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious "Cancer Moonshot" initiative. This ambitious plan, aimed at halving cancer rates within the next quarter-century, continues to fuel hope even as concerns about the stability of National Institutes of Health (NIH) funding arise. In these turbulent times, the resilience and ingenuity of the biotech sector provide a beacon of hope. For instance, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Zymeworks Inc. (NASDAQ: ZYME), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Protagonist Therapeutics, Inc. (NASDAQ: PTGX), and Amgen Inc. (NASDAQ: AMGN), have each demonstrated inspiring progress and unwavering commitment in advancing cancer treatments, highlighting their vital role in the future of cancer therapy.

Key Points: 
  • The oral presentation shared at the event described how they've been testing a treatment for advanced breast cancer, and it's looking very promising.
  • The treatment combines Oncolytics' flagship drug, pelareorep, with a well-known cancer medicine, paclitaxel.
  • Pelareorep is a unique drug that targets and kills cancer cells by making them self-destruct while leaving healthy cells unharmed.
  • It even lowered the risk of the cancer getting worse by a significant 71% compared to just using paclitaxel.

Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

Retrieved on: 
Friday, September 22, 2023

VANCOUVER, British Columbia, Sept. 22, 2023 /PRNewswire/ -- USA News Group - Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious "Cancer Moonshot" initiative. This ambitious plan, aimed at halving cancer rates within the next quarter-century, continues to fuel hope even as concerns about the stability of National Institutes of Health (NIH) funding arise. In these turbulent times, the resilience and ingenuity of the biotech sector provide a beacon of hope. For instance, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Zymeworks Inc. (NASDAQ: ZYME), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Protagonist Therapeutics, Inc. (NASDAQ: PTGX), and Amgen Inc. (NASDAQ: AMGN), have each demonstrated inspiring progress and unwavering commitment in advancing cancer treatments, highlighting their vital role in the future of cancer therapy.

Key Points: 
  • The oral presentation shared at the event described how they've been testing a treatment for advanced breast cancer, and it's looking very promising.
  • The treatment combines Oncolytics' flagship drug, pelareorep, with a well-known cancer medicine, paclitaxel.
  • Pelareorep is a unique drug that targets and kills cancer cells by making them self-destruct while leaving healthy cells unharmed.
  • It even lowered the risk of the cancer getting worse by a significant 71% compared to just using paclitaxel.

Credits roll on two weeks of unforgettable creations inspired by Campari, at 76th Festival de Cannes

Retrieved on: 
Sunday, May 28, 2023

CANNES, France, May 28, 2023 /PRNewswire/ -- As an official partner to the 76th edition of the world-renowned Festival de Cannes , Campari, the icon of cocktail culture inspired through a series of events that celebrated the unforgettable creations of mixology and of the cinema industry.

Key Points: 
  • CANNES, France, May 28, 2023 /PRNewswire/ -- As an official partner to the 76th edition of the world-renowned Festival de Cannes , Campari, the icon of cocktail culture inspired through a series of events that celebrated the unforgettable creations of mixology and of the cinema industry.
  • Throughout the Festival, the Campari Lounge and Palais de Stephanie Beach were transformed into the setting of afterparties for the unforgettable creations released at the 76th Festival de Cannes.
  • At THE IDOL Premiere after-party, Campari served its iconic beverages from an unmissable bar, inviting guests to celebrate another unforgettable creation.
  • During an evening dedicated to celebrating the creativity and passion of Campari brought together five of the world's best bartenders for CAMPARI: Celebrating Unforgettable Creations.

Credits roll on two weeks of unforgettable creations inspired by Campari, at 76th Festival de Cannes

Retrieved on: 
Sunday, May 28, 2023

CANNES, France, May 28, 2023 /PRNewswire/ -- As an official partner to the 76th edition of the world-renowned Festival de Cannes , Campari, the icon of cocktail culture inspired through a series of events that celebrated the unforgettable creations of mixology and of the cinema industry.

Key Points: 
  • CANNES, France, May 28, 2023 /PRNewswire/ -- As an official partner to the 76th edition of the world-renowned Festival de Cannes , Campari, the icon of cocktail culture inspired through a series of events that celebrated the unforgettable creations of mixology and of the cinema industry.
  • Throughout the Festival, the Campari Lounge and Palais de Stephanie Beach were transformed into the setting of afterparties for the unforgettable creations released at the 76th Festival de Cannes.
  • At THE IDOL Premiere after-party, Campari served its iconic beverages from an unmissable bar, inviting guests to celebrate another unforgettable creation.
  • During an evening dedicated to celebrating the creativity and passion of Campari brought together five of the world's best bartenders for CAMPARI: Celebrating Unforgettable Creations.

Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

Retrieved on: 
Wednesday, May 17, 2023

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors.
  • “Sarah is an accomplished healthcare executive with extensive global clinical development and corporate strategy experience,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus.
  • She has significant experience designing and leading rare disease programs from discovery to global regulatory approvals and commercialization.
  • “Marinus has emerged as a leader in the development of innovative treatment options for patients with genetic epilepsies and seizure disorders.

Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113

Retrieved on: 
Friday, May 12, 2023

NEWARK, Calif., May 12, 2023 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") reported data from its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), on Phase 1 and preclinical studies of JNJ-2113 (formerly PN-235), presented by Janssen and co-authored with Protagonist, as an oral presentation at the International Societies for Investigative Dermatology (ISID) 2023 meeting in Tokyo, Japan. The presentation, "First-in-class oral peptide systemically targeting the IL-23 pathway," is available online at isid2023.org for registered users.

Key Points: 
  • The presentation, "First-in-class oral peptide systemically targeting the IL-23 pathway," is available online at isid2023.org for registered users.
  • Highlights of the data presented on JNJ-2113 include the following:
    JNJ-2113 is a macrocyclic peptide that binds to the IL-23 receptor with single digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 signaling in human T cells.
  • Although peptides typically have low oral bioavailability, the high potency of JNJ-2113, along with its oral stability, indicated potential for systemic activity beyond the gastrointestinal tract in rat models of inflammation and colitis.
  • We look forward to the presentation of the Phase 2b FRONTIER 1 study data in adults with moderate-to-severe plaque psoriasis later this year."

Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference

Retrieved on: 
Thursday, May 11, 2023

NEWARK, Calif., May 11, 2023 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat presentation and host one-on-one meetings with investors at the JMP Securities Life Sciences Conference, an investor event taking place May 15-16, 2023 in New York, New York.

Key Points: 
  • NEWARK, Calif., May 11, 2023 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat presentation and host one-on-one meetings with investors at the JMP Securities Life Sciences Conference, an investor event taking place May 15-16, 2023 in New York, New York.

Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association

Retrieved on: 
Thursday, May 11, 2023

NEWARK, Calif., May 11, 2023 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that additional data from the REVIVE study of rusfertide in polycythemia vera will be presented in two posters at the annual Congress of the European Hematology Association (EHA), taking place June 8-11, 2023 in Frankfurt, Germany and virtually through June 15, 2023.

Key Points: 
  • NEWARK, Calif., May 11, 2023 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that additional data from the REVIVE study of rusfertide in polycythemia vera will be presented in two posters at the annual Congress of the European Hematology Association (EHA), taking place June 8-11, 2023 in Frankfurt, Germany and virtually through June 15, 2023.
  • Title: Pharmacokinetic and pharmacodynamic effects of rusfertide in polycythemia vera: Results from an ongoing Phase 2 study in patients with elevated hematocrit values

Metagenomi Appoints Sarah Noonberg, M.D., Ph.D. as Chief Medical Officer

Retrieved on: 
Tuesday, February 14, 2023

Metagenomi , a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, today announced the appointment of Sarah Noonberg, M.D., Ph.D. as Chief Medical Officer.

Key Points: 
  • Metagenomi , a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, today announced the appointment of Sarah Noonberg, M.D., Ph.D. as Chief Medical Officer.
  • In this role, Dr. Noonberg will oversee the clinical development of Metagenomi’s drug candidates and development strategy of the Company’s expanding therapeutic pipeline.
  • “Dr.
  • Earlier, she was Chief Medical Officer of Nohla Therapeutics, leading clinical development of a program for hematologic malignancies.